Reference Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Ref Type Abstract
PMID
Authors Yong Fang, Hongming Pan, Shun Lu, Hong Hu, Qin Lu
Title A phase I study to evaluate safety, tolerability, pharmacokinetics, and preliminary antitumor activity of TQ-B3101.
Journal Journal of Clinical Oncology
Vol 38
Issue 15_suppl
Date May 25, 2020
URL https://ascopubs.org/doi/10.1200/JCO.2020.38.15_suppl.e21705
Abstract Text Background: TQ-B3101 is a novel compound, which deacetylated metabolite targets to receptor tyrosine kinases including ALK, ROS1 and MET. Preclinical studies showed TQ-B3101 had a better Inhibition activity and duration compared with equimolar crizotinib. Methods: Patients (pts) with advanced solid tumor failed to standard therapy were enrolled into dose escalation and expansion cohorts. TQ-B3101 was orally administered at doses of 100~300mg QD or 200~350mg BID in a 28-day cycle, then received the same dose until disease progression or intolerable toxicity. Dose escalation was based on dose-limiting toxicities (DLTs) in the first cycle and used “3+3” design to get the maximal tolerated dose (MTD) or recommended phase II dose (RP2D). Other objectives included safety and pharmacokinetics (PK) for all pts, and objective response rate (ORR) for ALK+, ROS1+ and MET amplification pts. Results: As of 20 Dec 2019, 30 pts (median age 51.3, males: 16, females: 14, ALK+: 19, ROS1+: 6, MET amplification: 2, lung cancer: 27, asymptomatic brain metastasis: 8, ECOG PS 1: 30) were enrolled into 7 dose escalation cohorts and 2 dose expansion cohorts (350mg BID/ 300mg BID). One DLT (grade 3 ALT increased) occurred at 350 mg BID. The MTD has not been reached. The most common grade 3 adverse events were neutrophils count decreased (20%), ALT increased (6.67%), leucocyte counts decreased (3.33%) and QT internal prolongation (3.33%). Grade 3 adverse events rate were 40% in 350mg BID cohort and 16.67% in 300mg BID cohort. PK analyses indicated TQ-B3101 metabolized into its deacetylated product rapidly, and exposure (Cmax and AUC) of which generally increased in a dose-proportional manner. Tumor response was evaluated in 24 pts with ALK+/ROS1+/MET amplification. ORR were 62.5% (15/24) in all cohorts, and 87.5% (7/8) in 350mg BID cohort. In 8 pts with brain metastases at baseline, ORR was 62.5% (5/8) . In 22 pts without brain metastases at baseline, the incidence of brain metastasis was 4.55% (1/22). 1 patient with MET amplification is evaluable and the tumor response is PR. Conclusions: TQ-B3101 was well tolerated and showed preliminary antitumor activity in ALK+, ROS1+ and MET amplification pts. Recommended phase II dose (RP2D) might be 300mg BID according longtime safety data. Further anti-tumor research in pts with ROS1+ is under going as multicenter clinical study in China. (NCT03972189). Clinical trial information: NCT03019276.

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
Drug Name Trade Name Synonyms Drug Classes Drug Description
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
ROS1 rearrange Advanced Solid Tumor predicted - sensitive TQ-B3101 Case Reports/Case Series Actionable In a Phase I trial, TQ-B3101 treatment was well tolerated and resulted in an objective response rate (ORR) of 62.5% (15/24) in patients with ALK-positive, ROS1-positive, or MET-amplified advanced solid tumors, with an ORR of 62.5% (5/8) in patients with brain metastases (J Clin Oncol 38, 2020 (suppl 15; abstr e21705); NCT03019276). detail...
ALK rearrange Advanced Solid Tumor predicted - sensitive TQ-B3101 Phase I Actionable In a Phase I trial, TQ-B3101 treatment was well tolerated and resulted in an objective response rate (ORR) of 62.5% (15/24) in patients with ALK-positive, ROS1-positive, or MET-amplified advanced solid tumors, with an ORR of 62.5% (5/8) in patients with brain metastases (J Clin Oncol 38, 2020 (suppl 15; abstr e21705); NCT03019276). detail...